证券代码：600256 证券简称：广汇能源 公告编号：2026-012 广汇能源股份有限公司 2026年第一次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 ■ （四）表决方式是否符合《公司法》及《公司章程》的规定，会议主持情况等。 本次股东会表决方式符合《公司法》及《公司章程》的规定。本次会议由公司董事会召集，董事长韩士 发先生主持。 （五）公司董事和董事会秘书的列席情况 1、公司在任董事11人，列席11人，其中：董事张涛、闫军以通讯方式出席会议；独立董事吴中华、蔡 镇疆、甄卫军及高丽以通讯方式出席会议。 2、董事会秘书及高管出席情况：董事、副总经理兼董事会秘书阳贤现场出席会议；董事、总经理戚庆 丰，常务副总经理么士平，副总经理兼财务总监马晓燕及法务总监徐云现场出席会议；副总经理于永鑫 及安全总监勉玉龙以通讯方式出席会议。 二、议案审议情况 （一）非累积投票议案 1、议案名称：广汇能源股份有限公司关于2026年度投资框架与融资计划的议 ...

Core Viewpoint - The announcement details the progress of a share reduction plan by the company's director, Shen Baowei, who has reduced his holdings in the company as part of a personal financial decision, adhering to legal regulations and the previously disclosed plan [2][3]. Group 1: Share Reduction Plan - Shen Baowei plans to reduce his holdings by a maximum of 253,750 shares, representing 0.0631% of the company's total share capital, within a specified timeframe from December 10, 2025, to March 9, 2026 [2]. - As of the announcement date, Shen Baowei has reduced his holdings by a total of 169,375 shares, which is 0.0421% of the company's total share capital [2][3]. - The reduction is based on personal financial needs and complies with relevant laws and regulations, ensuring no insider trading or violations of the disclosed plan [3][4]. Group 2: Compliance and Impact - Shen Baowei has strictly adhered to the disclosed reduction plan, and the total shares reduced fall within the previously announced limits [3]. - The share reduction does not involve any insider information or sensitive period trading, and it will not affect the company's control structure or governance [3]. - The company will continue to monitor the progress of the share reduction plan and fulfill its disclosure obligations as required [4].

Group 1 - The company has appointed Mr. Zhang Jinbo as the General Manager and Mr. Hao Yuliang and Mr. Sun Quan as Deputy General Managers, effective from the date of the board meeting [1][2] - The appointments aim to enhance the company's governance structure and improve management efficiency in line with its strategic development [1] - The board confirmed that the appointed executives meet the qualifications required by the Company Law and other relevant regulations [2][7][8] Group 2 - The company held its second board meeting on February 3, 2026, where it also approved the supplementary election of members for the Technology Innovation Committee and the Nomination Committee [8][9] - Mr. Zhang Jinbo was elected as the Chairman of the Technology Innovation Committee, and Ms. Li Jie was elected as a member of the Nomination Committee, with terms lasting until the end of the current board's tenure [9][10][11] - The adjustments in committee memberships were made to ensure the smooth operation of the board's committees following changes in board membership [9]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603103 证券简称：横店影视 公告编号：2026-004 横店影视股份有限公司 股票交易异常波动暨风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 横店影视股份有限公司（以下简称"公司"）股票于2026年2月2日、2月3日连续2个交易日内日收盘价 格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动的 情形。 ● 公司股票已连续4个交易日（2026年1月29日、1月30日、2月2日、2月3日）内日收盘价格涨停，股价 剔除大盘和板块整体因素后的实际涨幅较大。存在公司股票短期上涨过快可能出现的下跌风险。 ● 截至2026年2月2日收盘，公司市盈率（TTM）为192.86，高于传媒行业市盈率（TTM）49.93。公司 郑重提醒广大投资者，注意二级市场交易风险。 ● 公司已于1月31日发布《横店影视股份有限公司股票交易异常波动公告》（公告编号：2026-002）， 于2月3日发布《横店影视股份有限公司股 ...

Core Viewpoint - The company, Yiyang Xintong Co., Ltd., is making a strategic investment of RMB 50.08 million in the Beijing Jiazhi Xincheng Equity Investment Fund, representing a 9.98% stake, to explore opportunities in high-tech and high-end manufacturing sectors, while ensuring that its main business operations remain unaffected [2][27]. Group 1: Investment Details - The total subscribed capital of the partnership is RMB 500.78 million, with Yiyang Xintong contributing RMB 50 million [2][5]. - The investment does not constitute a related party transaction or a major asset restructuring as per relevant regulations [2][5]. - The investment will not require approval from the company's board of directors or shareholders [2][5]. Group 2: Partnership Overview - The company will partner with Guoke Jiahe (Beijing) Investment Management Co., Ltd. as the general partner and other limited partners to establish the fund [5]. - The fund aims to invest in high-quality enterprises that align with national industrial policies, focusing on technological innovation and high-efficiency sectors [27]. Group 3: Fund Management and Investment Strategy - The fund will be managed by the general partner, Guoke Jiahe, who will have full authority over investment decisions and management [9][19]. - The investment strategy will include equity investments in non-listed companies, with a focus on value investment and industry development [10][18]. Group 4: Financial Impact - The investment is expected to enhance the company's investment and business cooperation channels, optimize its capital and asset structure, and improve shareholder returns [27]. - The funding source for this investment is the company's own funds, ensuring that normal business operations are not impacted [27].

Core Viewpoint - Beijing Hotgen Biotech Co., Ltd. is progressing with the sale of repurchased shares to maintain company value and shareholder rights, following regulatory guidelines [2][3]. Group 1: Share Repurchase Overview - The company repurchased a total of 2,893,010 shares from February 8, 2024, to May 7, 2024, representing 3.12% of the current total share capital [2]. - The repurchased shares will be sold through centralized bidding within twelve months after the announcement of the repurchase results [2]. Group 2: Sale Plan Progress - The company plans to sell up to 1,854,158 shares through centralized bidding from January 19, 2026, to July 18, 2026 [3]. - The sale plan was approved during the fourth board meeting on December 23, 2025, in accordance with the repurchase report [3]. Group 3: Sale Implementation Details - The company is required to disclose the sale progress at the beginning of each month, adhering to regulatory requirements [5]. - The sale plan is consistent with previously disclosed plans and commitments, with no major events like stock splits or mergers planned during the sale period [5]. Group 4: Impact of the Sale - The sale aligns with the company's established plan and relevant regulations, with proceeds intended to supplement the company's working capital [6].

东鹏饮料（集团）股份有限公司 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：605499 证券简称：东鹏饮料 公告编号：2026-014 关于H股挂牌并上市交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 东鹏饮料（集团）股份有限公司（以下简称"公司"）正在进行申请发行H股股票并在香港联合交易所有 限公司（以下简称"香港联交所"）主板上市（以下简称"本次发行上市"）的相关工作。 公司本次全球发售H股总数为40,889,900股（行使超额配售权之前），其中，香港公开发售4,089,000 股，约占全球发售总数的10.00％（行使超额配售权之前）；国际发售36,800,900股，约占全球发售总数 的90.00％（行使超额配售权之前）。根据每股H股发售价248.00港元计算，经扣除全球发售相关承销佣 金及其他估计费用后，并假设超额配售权未获行使，公司将收取的全球发售所得款项净额估计约为 99.94亿港元。 经香港联交所批准，公司本次发行的40,889,900股H股股票（行使超额配售权之前）于2026年2月3日 ...

Group 1 - Zhiyang Innovation (688191) announced plans to acquire control of Shenzhen Lingming Photon Technology Co., Ltd. through stock issuance, convertible bonds, and cash payments, while also raising supporting funds [2] - The transaction is expected to constitute a major asset restructuring as defined by the regulations and is anticipated to involve related party transactions, but will not result in a change of control for the company [2] - The company is currently in the planning stage of the transaction and has engaged in preliminary discussions with key parties, including signing a letter of intent with Lingming Technology [2] Group 2 - Zhiyang Innovation focuses on digital and intelligent transformation in various industries, providing AI solutions through a comprehensive product system that includes algorithms, software, and hardware [3] - Lingming Photon is recognized for its development of high-performance single-photon detection chips, which are essential for 3D perception in modern electronic devices, and has received significant investment for technology upgrades and production capacity enhancement [4] - The company is involved in ongoing litigation with Suteng Company regarding intellectual property rights, which is viewed as a significant case in the laser radar chip sector [5][6]

上海复星医药（集团）股份有限公司 关于2026年度第一期科技创新债券发行完成的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、中期票据额度注册及历次发行情况 中国银行间交易商协会于2025年3月20日出具《接受注册通知书》（中市协注[2025]MTN272号）（以下 简称"通知书"），接受上海复星医药（集团）股份有限公司（以下简称"本公司"）中期票据注册，注册 额度为人民币40亿元，该额度有效期自通知书出具日起2年（以下简称"注册有效期"），并可分期发 行。 证券代码：600196 股票简称：复星医药 编号：临2026-015 近日，本公司于上述注册额度内完成2026年度第一期科技创新债券（以下简称"本期债务融资工具"）的 发行，现将发行结果公告如下： ■ 本期债务融资工具发行详情及有关文件请见中国货币网（https://www.chinamoney.com.cn）和上海清算 所网站（https://www.shclearing.com.cn）。 特此公告。 上海复星医药（集团）股份有限公司 董事会 二零二六年二月三 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600846 证券简称：同济科技 公告编号：2026-006 上海同济科技实业股份有限公司 关于集中竞价减持已回购股份进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 回购股份基本情况：为维护公司价值及股东权益，上海同济科技实业股份有限公司（以下简称"公 司"）于2024年8月21日至2024年10月17日期间通过集中竞价交易方式回购公司股份4,415,520股（占公司 总股本的比例为0.7068%）。详见公司于2024年10月18日披露的《关于股份回购实施结果暨股份变动的 公告》（公告编号：2024-050）。 ● 减持计划的进展情况：2025年10月22日，公司在上海证券交易所网站（www.sse.com.cn）披露《关于 集中竞价减持已回购股份计划的公告》（公告编号：2025-037）。公司计划自该公告披露之日起15个交 易日后的3个月内，通过集中竞价方式减持不超过4,415,520股（不超过公司总股本的0.7068%）回购股 份。若 ...